As 2020 begins, all of us here at ClinTex thought a news update for our followers was long overdue — our apologies for the lack of recent public posting, the team has been busy building, developing and testing our CTi project. We hope this roundup provides a clear picture of the progress we’ve made over the past 18 months.

We want to give a special thanks to our partners and extended team who’ve made all this progress possible.

Together we will continue our mission to drive down the cost of new medicine through the advancement of faster, more efficient and cost effective clinical trials.

Q3 2018: CLX Token Sale pushed out to allow for Development, now scheduled for 2020

After extensive consultation with stakeholders in the pharma industry and regulators (FDA and EMA), ClinTex agreed to a set of further developments to the CTi platform to address some immediate needs in terms of functionality for regulatory compliance.

It was decided that doing this in advance of our fundraise via token sale would ensure a smooth transition of the CTi platform into live clinical trial environments, thus improving early uptake and on-boarding of clients without delay post token sale.

Another prominent factor considered by the ClinTex management team was how best to generate and protect value for our CLX token holders post token sale given the negative market conditions in September 2018.

The outcome of these considerations was that a decision was taken by management to delay the CLX token sale, both to allow time for the aforementioned CTi platform developments to be completed, and concurrently to allow market conditions to stabilise.

Now having completed the necessary functionality upgrades for regulatory compliance, and with market conditions now more stable, ClinTex are delighted to confirm that we intend to launch the token sale in the first half of this year on a prominent cryptocurrency exchange. Please stay tuned to our media channels for further announcements.

Q4 2018: CTi Platform Development Reaches Key Milestone

By September of 2018, ClinTex were proud to have reached Minimum Viable Product status on both the CTi Data Model design and the ClinTex Operational Efficiency Application (CTi-OEM).

More info…

Q2 2019: Partnership with Intellimed Renewed

Pursuant to our need to access existing clinical trial data for the purposes of training and enhancing our CTi data analytics engine, continued partnership with established health-tech player Intellimed was critical.

More info…

Q3 2019: European Medicines Agency Data Integrated to CTi

Taking a huge step towards commercialisation of our offerings for the pharmaceutical industry, in August of 2019 we populated the CTi platform with real world clinical trial data from the European Medicines Agency. This enabled us to refine our ETL (extract, transform, load) data integration process and improve data analytics.

More info…

Q1 2020: Insights Delivered for Late Phase Clinical Trials

Using data from three late-phase clinical trials, our CTI-OEM app was able to deliver a number of operational insights that would be valuable for pharmaceutical companies looking to improve their clinical trials operations efficiency. Namely, our data analytics showed correlations between key performance indicators such as early withdrawal rates of patients, data query rates, and time to data entry. These correlations form an important step for proving the viability of our Predictive Data Analytics Application (CTi-PDA) which, in line with our new road map, is scheduled for development in 2021.

More info…